PharmaNet Development Names Maida Vice President of Clinical Research

PharmaNet Development Group Inc. named Anthony Maida vice president of clinical research. Maida will lead the oncology team at the provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries. He previously had his own consulting firm. JLL Partners added the Princeton, N.J.-based company to its portfolio in March 2009.

PRESS RELEASE

PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that Anthony Maida, PhD has joined the Company as Vice President, Clinical Research. Dr. Maida will be responsible for leading PharmaNet’s oncology team.

“Anthony’s experience spans the drug development process. He has a unique strength in his well balanced expertise across strategic, operational and financial aspects of the business,” said Dr. Robert Reekie, Chief Operating Officer and Senior Executive Vice President, Late Stage Development. “We are pleased to have Anthony as part of our outstanding oncology team.”

TD

Dr. Maida has more than twenty years of experience providing strategic, operational, and financial expertise to pharmaceutical companies that are focused primarily in the area of oncology. Most recently, he ran his own consulting firm providing both pharmaceutical product development and capital raising capabilities to pharmaceutical firms, working with venture capital funds and investment banks. Prior to joining the pharmaceutical industry, Dr. Maida worked for Lockheed Corporation in a number of key financial roles.

Dr. Maida earned Bachelor of Arts degrees from the University of Santa Clara and San Jose State University, a Masters of Business Administration degree from the University of Santa Clara, a Masters degree in Toxicology from San Jose State University and a PhD in Tumor Immunology, from the University of California, Davis.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.